Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib in type I cryoglobulinemic vasculitis: are we acting too late?
Ramirez GA, Campochiaro C, Salmaggi C, Pagliula G, D'Aliberti T, Marcatti M, Tresoldi M, Praderio L. Ramirez GA, et al. Among authors: marcatti m. Intern Med. 2015;54(9):1119-23. doi: 10.2169/internalmedicine.54.3668. Epub 2015 May 1. Intern Med. 2015. PMID: 25948361 Free article.
Essential mixed cryoglobulinemia: a report on 14 cases.
Silvestris M, Praderio L, Peccatori S, Marcatti M, Storti M, Ciboddo G, Rugarli C. Silvestris M, et al. Among authors: marcatti m. Boll Ist Sieroter Milan. 1989;68(2):174-9. Boll Ist Sieroter Milan. 1989. PMID: 2562363
Iron increases the susceptibility of multiple myeloma cells to bortezomib.
Campanella A, Santambrogio P, Fontana F, Frenquelli M, Cenci S, Marcatti M, Sitia R, Tonon G, Camaschella C. Campanella A, et al. Among authors: marcatti m. Haematologica. 2013 Jun;98(6):971-9. doi: 10.3324/haematol.2012.074872. Epub 2012 Dec 14. Haematologica. 2013. PMID: 23242599 Free PMC article.
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.
Bringhen S, Offidani M, Palmieri S, Pisani F, Rizzi R, Spada S, Evangelista A, Di Renzo N, Musto P, Marcatti M, Vallone R, Storti S, Bernardini A, Centurioni R, Aitini E, Palmas A, Annibali O, Angelucci E, Ferrando P, Baraldi A, Rocco S, Andriani A, Siniscalchi A, De Stefano V, Meneghini V, Palumbo A, Grammatico S, Boccadoro M, Larocca A. Bringhen S, et al. Among authors: marcatti m. Crit Rev Oncol Hematol. 2018 Oct;130:27-35. doi: 10.1016/j.critrevonc.2018.07.003. Epub 2018 Jul 18. Crit Rev Oncol Hematol. 2018. PMID: 30196909 Free article. Review.
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?
Marchica V, Accardi F, Storti P, Mancini C, Martella E, Dalla Palma B, Bolzoni M, Todoerti K, Marcatti M, Schifano C, Bonomini S, Sammarelli G, Neri A, Ponzoni M, Aversa F, Giuliani N. Marchica V, et al. Among authors: marcatti m. Int J Hematol. 2017 Jan;105(1):104-108. doi: 10.1007/s12185-016-2104-1. Epub 2016 Oct 3. Int J Hematol. 2017. PMID: 27699576
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.
Oliva L, Orfanelli U, Resnati M, Raimondi A, Orsi A, Milan E, Palladini G, Milani P, Cerruti F, Cascio P, Casarini S, Rognoni P, Touvier T, Marcatti M, Ciceri F, Mangiacavalli S, Corso A, Merlini G, Cenci S. Oliva L, et al. Among authors: marcatti m. Blood. 2017 Apr 13;129(15):2132-2142. doi: 10.1182/blood-2016-08-730978. Epub 2017 Jan 27. Blood. 2017. PMID: 28130214 Free article.
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Montefusco V, Corso A, Galli M, Ardoino I, Pezzatti S, Carniti C, Patriarca F, Gherlinzoni F, Zambello R, Sammassimo S, Marcatti M, Nozza A, Crippa C, Cafro AM, Baldini L, Corradini P. Montefusco V, et al. Among authors: marcatti m. Br J Haematol. 2020 Mar;188(6):907-917. doi: 10.1111/bjh.16287. Epub 2020 Jan 2. Br J Haematol. 2020. PMID: 31898319 Free article.
77 results